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ABSTRACT
Objective: To characterize peripheral nerve involvement in patients with chronic progressive
external ophthalmoplegia (CPEO) with single and multiple mitochondrial DNA (mtDNA) deletions,
based on clinical scores and detailed nerve conduction studies.
Methods: Peripheral nerve involvement was prospectively investigated in 33 participants with
CPEO (single deletions n 5 18 and multiple deletions n 5 15). Clinically, a modified Total
Neuropathy Score (mTNS) and a modified International Cooperative Ataxia Rating Scale
(mICARS) were used. Nerve conduction studies included Nn. suralis, superficialis radialis, tibia-
lis, and peroneus mot. Early somatosensory evoked potentials were obtained by N. tibialis
stimulation.
Results: Participants with multiple deletions had higher mTNS and mICARS scores than those
with single deletions. Electrophysiologically in both sensory nerves (N. suralis and N. radialis
superficialis), compound action potential (CAP) amplitudes and nerve conduction velocities were
lower and mostly abnormal in multiple deletions than those in single deletions. Early somatosen-
sory evoked potentials of N. tibialis revealed increased P40 latencies and decreased N35-P40
amplitudes in multiple deletions. Both sensory nerves had higher areas under the receiver oper-
ating characteristic curves for the decreased CAP amplitudes than the 2 motor nerves. The N.
suralis had the best Youden index, indicating a sensitivity of 93.3% and a specificity of
72.2% to detect multiple deletions.
Conclusions: Peripheral nerve involvement in participants with multiple mtDNA deletions is an
axonal type of predominant sensory neuropathy. This is clinically consistent with higher mTNS
and mICARS scores. Sensory nerve involvement in participants with multiple deletions was not
correlated with age at onset and duration of disease. Neurol Genet 2016;2:e113; doi: 10.1212/
NXG.0000000000000113
GLOSSARY
AUC 5 area under the curve; CAP 5 compound action potential; CPEO 5 chronic progressive external ophthalmoplegia;
mICARS 5 modified International Cooperative Ataxia Rating Scale; mtDNA 5 mitochondrial DNA; mTNS 5 modified Total
Neuropathy Score; NCV 5 nerve conduction velocity; SANDO 5 sensory ataxic neuropathy with dysarthria and
ophthalmoparesis.
Chronic progressive external ophthalmoplegia (CPEO) is the main clinical symptom associated
with single, large scale, and multiple deletions of mitochondrial DNA (mtDNA). Peripheral
neuropathy is a typical but variably expressed additional symptom.1–3 However, reports about
peripheral neuropathy in patients with single deletions are rare.4–6 Electrophysiologic studies in
mitochondrial diseases usually revealed a predominantly axonal type of nerve fiber damage.7–15
However, a predominantly demyelinating pattern or a mixed axonal and demyelinating type of
peripheral nerve involvement has also been found.4,11,16 Sural nerve biopsies revealed axonal
degeneration12,13 or demyelination.11 It has already been shown that patients with multiple
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deletions (clinically SANDO [sensory ataxic
neuropathy with dysarthria and ophthalmopa-
resis] syndrome) had reduced compound
action potential (CAP) amplitudes in predom-
inantly sensory nerves. Clinically, they might
often present as SANO or SANDO syn-
drome.17 There is only one previous study sys-
tematically comparing peripheral nerve
involvement in patients with CPEO with sin-
gle and multiple mtDNA deletions.18 In that
study, it has been postulated that peripheral
neuropathy is a rare finding in patients with
CPEO with single deletions compared with
that in patients with CPEO with mtDNA
point mutations, multiple mtDNA deletions,
and nuclear defects. However, in that study,
only one patient with single mtDNA deletion
and peripheral nerve involvement has been
investigated. Four other patients had the typical
mitochondrial encephalomyopathy, lactic aci-
dosis, and stroke-like episode mtDNA point
mutation. Nine other patients had the nuclear
POLG mutation, but multiple deletions have
not been analyzed in 3/9 patients. In 2 patients
with multiple deletions, the nuclear defect has
not been identified. In all these patients, no
detailed clinical and neurophysiologic data were
presented, and no quantitative electrophysio-
logic data were provided.18
In the present study, peripheral nerve
involvement was prospectively investigated in
33 participants who had CPEO (single dele-
tions n5 18 and multiple deletions of nuclear
defects n 5 15). Based on clinical scores and
detailed nerve conduction studies, it could be
shown that there was a more severe predomi-
nant sensory neuropathy in participants with
multiple than with single deletions.
METHODS Participants. A total of 33 participants with
CPEO associated with mtDNA deletions were included (single
deletions n 5 18 participants and multiple deletions n 5 15
participants). The whole period of participants’ recruitment was
4 years. Single deletions varied in length between 2 and 6.5 kb
(median 5). The common 4.9 kb deletion was identified in 4
patients. The nuclear defects are shown in table 1. The nuclear
molecular defect of 1 participant could not be identified (ANT1,
Twinkle, POLG1, and POLG2 were investigated). Genetic find-
ings of 3 participants with multiple deletions were published
previously.19,20 Clinical data of participants with multiple and
single deletions are shown in table 2.
Standard protocol approvals and participant consent.
Genetics, electrophysiologic studies, and data analysis were per-
formed in compliance with protocols approved by the Ethical
Committee of the Martin Luther University Halle-Wittenberg.
Written informed consent was obtained from all participants.
Procedure. Multiple and single deletions have been detected by
Southern blot analysis and long-range PCR analysis. Genetic
studies have been performed according to standard protocols. All
33 participants were clinically characterized using a modified
Total Neuropathy Score21 (mTNS) (table 3) and a modified
International Cooperative Ataxia Rating Scale22 (mICARS)
(supplemental data at Neurology.org/ng). The modification of
mTNS included the following points: the sensibility was
examined and rated according to the clinical-neurologic
examination; the autonomic symptoms were elicited. mICARS
calculation: maximum were 94 points instead of 100 points
because examination of eye movement in patients with CPEO
had to be omitted. Electrophysiologic studies included nerve
conduction studies of sensory nerves (N. suralis and N. sup.
radialis), motor nerves (N. tibialis and N. peroneus.), and evoked
potentials of the N. tibialis (P40 latency and N35-P40 amplitude
values). Nerves without measurable amplitude and therefore
without measurable nerve conduction velocity (NCV) in
electrophysiologic studies have been omitted from statistical
analysis. However, these nerves have been separately indicated in
the analysis of the age dependence of the neurographic results.
Normal limits for electrophysiologic studies were assessed
according to Oh.23
RESULTS Clinical scores: mTNS and mICARS. Partic-
ipants with single and multiple deletions both had
abnormal mTNS and mICARS scores. However,
both scores were higher in participants with multiple
than those with single deletions (table 2). Two of
15 patients with multiple deletions presented with
SANDO phenotype. In these 2 participants, neurog-
raphy indicated a non–length-dependent neuropathy.
Table 1 Summary of genetic data of 15
participants with multiple deletions
Sex Molecular defect
M ANT1: p.A90Da (heterozygote)
M ANT1: p.A90Da (heterozygote)
M POLG: p.G848S/p.A899Tb (heterozygote)
F POLG: p.G848S/p.A899Tb (heterozygote)
M POLG: p.A467T/p.A467Tb (homozygote)
M POLG: p.A467T/p.W748Sb (heterozygote)
F POLG: p.Ala467Thr/p.Met919Leu (heterozygote)
F POLG: p.T251I/p.P587L/p.R627Qb (heterozygote)
F POLG: p.Thr251Ile/p.Pro587Leub (heterozygote)
F Twinkle (PEO1): p.K319Ta (heterozygote)
F Twinkle (PEO1): p.Arg354Proa (heterozygote)
M Twinkle (PEO1): p.Lys319Glua (heterozygote)
M Twinkle (PEO1): p.Lys319Glua (heterozygote)
F Twinkle (PEO1): p.Met114Arg/p.Met455Valb
(heterozygote)
F Not detected
aDominant mutation.
bRecessive mutation.
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Neurography. The differences of CAP and NCV in
participants with single and multiple deletions were
significant (figure 1, A and B). Sensory CAPs of the
sural nerve were absent bilaterally in 7 and unilater-
ally in further 3/15 participants with multiple
mtDNA deletions in contrast to bilateral absence in
2/18 participants with single mtDNA deletions. Early
somatosensory evoked potentials of N. tibialis stimu-
lation showed in participants with multiple mtDNA
deletions an increase of P40 latency (p , 0.005),
while the N35-P40 amplitudes (p , 0.00005) were
reduced, compared with participants with single
mtDNA deletions. In participants with multiple
deletions, there was no correlation between age at
onset or duration of disease with NCVs (figure 1,
C–F) or CAP amplitudes (figure e-1). The 2
patients with SANDO were included in the overall
cohort for the neuropathy/ataxia scores and all
electrophysiologic studies. Reexamination of the
data excluding the 2 patients with SANDO did not
change the statistical results of the mICARS, mTNS,
or electrophysiologic studies.
Statistical analysis of sensitivity and specificity of
both sensory nerves (N. suralis and N. sup. radialis)
showed the highest AUC (area under the [receiver
operating characteristic] curve) levels. However,
despite a higher AUC level, the N. suralis showed
a better Youden index (figure 2). The decreased
CAP amplitudes of the N. suralis had a sensitivity
of 93.3% and a specificity of 72.2% (positive predic-
tive value 5 73.7% and negative predictive value 5
92.9%) to detect multiple deletions.
DISCUSSION Peripheral neuropathy is a well-
known clinical feature in mitochondrial diseases. In
a large phenotype/genotype analysis of 136 patients
with CPEO with single mtDNA deletions,
polyneuropathy has not been mentioned as
a clinical finding.6 Another group found peripheral
neuropathy in 8% of patients with CPEO with single
mtDNA deletions.5 However, peripheral neuropathy
has also been reported in 32% of patients with
multiple mtDNA deletions due to mutations in the
gene encoding polymerase gamma as well.24 Recently,
1 single deletion patient who had peripheral nerve
involvement has been studied.18
In the present study, both groups of participants
(single and multiple deletions) had higher mTNS
and mICARS scores than normal. However, partici-
pants with multiple deletions had higher mTNS
(p , 0.001) and mICARS (p 5 0.009) values as
Table 3 Modified Total Neuropathy Score
0 1 2 3 4
Sensory symptoms None Toes or fingers only Up to malleoli or wrist Up to knee or elbow Proximal sites involved
Motor symptoms None Minor difficulties Moderate difficulties Patient dependent Patient paralyzed
Foot drop Foot orthosis required Walking with cane Wheelchair dependent
Difficulties with
buttoning
Buttoning impossible, writing with
difficulties
Unable to write Proximal arm weakness
Autonomic symptomsa
Pallesthesia None Diminished in toes or
fingers
Reduced at malleoli or wrist Reduced up to knee or
elbow
Reduced above elbow or
knee
Paresis None MRC 4 MRC 3 MRC 1–2 MRC 0
Reflexes Normal Ankle reflex weakened Ankle reflex absent Other reflexes weakened Areflexia
Sural nerve amplitude .95% 76%–95% of normal 51%–75% of normal 26%–50% of normal 0%–25% of normal
Peroneal nerve amplitude .95% 76%–95% of normal 51%–75% of normal 26%–50% of normal 0%–25% of normal
Abbreviation: MRC 5 Medical Research Council.
a Urinary incontinence, imperative micturition, erectile dysfunction, fecal incontinence, vomiting, diarrhea, and orthostatic hypotension.
Table 2 Clinical data of participants with single and multiple mtDNA
deletions, 6SD
Single mtDNA
deletion
sample (n 5 18)
Multiple mtDNA
deletion
sample (n 5 15)
Statistical
significance
Sex (F/M) 18 (12/6) 15 (8/7) NS
Age, y 49 6 13 57 6 12 NS
Age at onset, y 27 6 14 42 6 15 p , 0.01
Duration of disease, y 22 6 4 15 6 3 NS
Heart block 2/10 3/15 NS
Retinopathy 5/17 0/13 p 5 0.052
Diabetes mellitus 3/18 3/15 NS
SANDO 0/18 2/15 NS
mTNS 4.6/32 6 3.5 12.5/32 6 6.3 p , 0.001
mICARS 6.7/94 6 4.9 15.5/94 6 10.9 p , 0.001
Abbreviations: mICARS 5 modified International Cooperative Ataxia Rating Scale;
mtDNA 5 mitochondrial DNA; mTNS 5 modified Total Neuropathy Score; NS 5 not signif-
icant; SANDO 5 sensory ataxic neuropathy with dysarthria and ophthalmoparesis.
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compared to those with single mtDNA deletions.
However, the ICARS is validated for cerebellar dis-
orders only, and high scores can therefore not be
considered as proof of sensory ataxia. In fact, patients
with CPEO may very well have high scores on the
ICARS scale because of myogenic dysarthria or
impaired gait due to cerebellar involvement or limb
girdle weakness.
Participants with single mtDNA deletions appear
to have an earlier age at onset (second decade of life)
than patients with multiple mtDNA (age at onset:
fourth decade of life). This is consistent with a further
study.25 Recently, it has been shown that patients with
single and multiple mtDNA deletions do not have
differences in histopathologic analysis.26 Peripheral
nerve involvement in multiple deletions did not corre-
late either with age at onset or duration of disease,
indicating that peripheral nerve involvement is a symp-
tom not influenced by age at onset or duration of
disease. Thus, the difference in age at onset in multiple
and single mtDNA deletions can so far only be stated.
The biological explanation remains enigmatic.
Electrophysiologically in both sensory nerves
(N. suralis and N. radialis superficialis), CAP
Figure 1 Electrophysiologic studies and age dependence of nerve conduction velocity in multiple deletions
(A) Compound action potential (CAP) amplitudes of the N. suralis (single deletions n 5 18 and multiple deletions n 5 15),
N. sup. radialis (single deletions n 5 18 and multiple deletions n 5 15), N. tibialis (mot.) (single deletions n 5 18 and multiple
deletions n5 15), and N. peroneus (mot.) (single deletions n5 18 and multiple deletions n5 14). *p, 0.005; **p, 0.0005;
***p, 0.000001 (Mann-Whitney U test). Bar shows the range of values. Dotted lines indicate limits of normal according to
Oh.23 (B) Nerve conduction velocity (NCV) of N. suralis (single deletions n 5 16 and multiple deletions n 5 8), N. sup. radialis
(single deletions n 5 18 and multiple deletions n 5 12), N. tibialis (mot.) (single deletions n 5 18 and multiple deletions n 5
14), and N. peroneus (mot.) (single deletions n 5 18 and multiple deletions n 5 14). *p , 0.05; **p , 0.005; ***p , 0.001
(Mann-Whitney U test). n.s. 5 not statistically significant. Bar shows the range of values. Dotted lines indicate limits of
normal according to Oh.23 (C) Correlation of age at onset with NCV N. suralis (n 5 8): p 5 0.3, r 5 20.4. (D) Correlation of
duration of disease with NCV N. suralis (n5 8): p5 0.3, r5 0.5. (E) Correlation of age at onset with NCV N. sup. radialis (n5
12): p 5 0.1, r 5 20.5. (F) Correlation of duration of disease and NCV N. sup. radialis (n 5 12): p 5 0.3, r 5 0.3. Gray dots
indicate nerves without measurable amplitude and therefore without measurable NCV.
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amplitudes and NCV were lower and mostly abnor-
mal in participants with multiple deletions. These
findings are consistent with those of a previous
study.17 The 2 motor nerves showed only slight dif-
ferences. The 2 sensory nerves showed decreased CAP
amplitudes and slightly decreased NCV values. This
suggests that the nerve involvement is predominantly
axonal. Fibers of the radial nerve were affected simi-
larly to those of the sural nerve. Thus, length depen-
dence is questionable in participants with multiple
mtDNA deletions. The sensory involvement was sup-
ported by early somatosensory evoked potentials,
showing that participants with multiple mtDNA de-
letions had an increase of P40 latency (p , 0.005),
while the according N35-P40 amplitude values were
reduced (p , 0.00005).
In a previous study, it has been shown that the
number of dorsal root ganglion cells and also poste-
rior horn cells was lower in a patient with pA467T/
pX1240Q mutations of the POLG gene as compared
to that in control subjects.3 Anterior horn cells were
also relatively low in number in this patient, but the
difference to the controls did not reach significance.3
Therefore, it can be hypothesized that sensory neu-
ropathy in patients with multiple mtDNA deletions is
not only of the axonal type but also might addition-
ally be caused by nerve cell loss.
Recently, it has been shown that peripheral neurop-
athy in patients with mitochondrial ophthalmoplegia
had the highest specificity (91%) for the diagnosis of
a nuclear DNA defect.18 In the same study, it has been
suggested that peripheral neuropathy is a rare finding
in patients with single deletions. This is consistent with
the present study. Electrophysiologically, both sensory
nerves CAP amplitudes and NCV were lower and
mostly abnormal in multiple deletions than those in
single deletions. However, in the previous study, large
fiber peripheral neuropathy was found in only 16/77
patients. Large deletions were seen in 9 of these 16
patients. Of the remaining 5 patients, 1 was a single
deletions and 4 were point mutations.18 In the present,
decreased CAP amplitudes of the sural nerve had a sen-
sitivity of 93.3% and a specificity of 72.2% (positive
predictive value5 73.7% and negative predictive value
5 92.9%) to detect multiple deletions.
Clinical and electrophysiologic findings of pre-
dominant sensory nerve involvement support the
notion that sensory neuropathy is not restricted to
SANDO syndrome but rather indicates that periph-
eral sensory nerve involvement is frequent in patients
with multiple deletions caused by nuclear defects.
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